2. CLINICAL CASE
A 45-year-old woman with a history of blood transfusion is
seen in the clinic for complaints of tiredness, fatigue, anorexia,
and weakness.
On Physical examination, nothing was remarkable
Laboratory values reported today include AST 150 IU/mL,
ALT 250 IU/mL , SCr 0.9 mg/dL,
Bilirubin: 2.0 mg/dL, albumin 2.5 g/dL.
Serum Anti HCV : + HCV RNA level: 1, 220200 IU/mL
A liver biopsy has revealed severe necro-inflammation and
bridging fibrosis.
What is diagnosis ?
What is the best course of action?
2
3. ILO’S
At the end of the session, the attendee will be able to
Define the acute and chronic viral hepatitis C
Diagnose based upon clinical and lab data
Design therapeutic objectives
Design therapeutic and follow up evaluation plan for patient
Resolve drug related problems of patient
Educate the patient to improve therapeutic outcome
DR. ARMAAN SINGH 3
4. INTRODUCTION
In 60’s only A & B
In 70’s, it was found that neither agent is found responsible for post
trans fusion Hepatitis, So Hepatitis caused by NANB was introduce
The major cause of parenterally transmitted NANB hepatitis. In 1989,
the genome was cloned from the serum of an infected chimpanzee.
FEB, 17, 2015DR. ARMAAN SINGH 4
5. INTRODUCTION: FACT SHEET
An estimated 130–170 million people are infected with
hepatitis C worldwide
Out of 100 people who contract the infection, 75–85% will
develop chronic infection,
60–70% develop chronic liver disease,
5–20% develop cirrhosis over the course of their chronic
infection,
1–5% will die of complications including hepatocellular
carcinoma (HCC)
7.3 % individuals were found seropositive for Anti-HCV
antibodies in a study carried out on 15323 Saudi patients
FEB, 17, 2015DR. ARMAAN SINGH 5
6. FEB, 17, 2015DR. ARMAAN SINGH 6
Figure 1. Seroprevalence of anti-HCV antibodies using chemiluminescent microparticle immunoassay.
Abdel-Moneim AS, Bamaga MS, Shehab GMG, Abu-Elsaad A-ASA, et al. (2012) HCV Infection among Saudi Population: High
Prevalence of Genotype 4 and Increased Viral Clearance Rate. PLoS ONE 7(1): e29781. doi:10.1371/journal.pone.0029781
http://www.plosone.org/article/info:doi/10.1371/journal.pone.0029781
The total seroprevalence among the 15323 tested individuals. B. HCV
seroprevalence in males in comparison to females
7. HCV
HCV is a single stranded RNA virus
Genus Hepa-civirus, (HCV)
Family Flavi-viridae
Characterized by a high spontaneous mutation rate
11 genotypes (90 sub-types) , (1a, 1,b, 2a, 3b etc)
USA:
Genotype 1 (subtypes 1a, 1b, and 1c) 70%–75%.
Genotypes 2 (subtypes 2a, 2b, and 2c) and 3 (3a and 3b) are less common
KSA:
Genotype 4 is common
Ia And Ib less common
Genotype 2, 3, 5 and 6 are least common
FEB, 17, 2015DR. ARMAAN SINGH 7
Genotype helps determine therapy
duration and likelihood of responding to
therapy
8. EPIDEMIOLOGY
Worldwide seroprevalence 3% based upon anti- HCV) up to 180 million
people infected chronically.
Variation in distribution 0.4% to 1.1% in North America to 9.6% to 13.6% in
North Africa.
A primary cause of death from liver disease
The leading indication for liver transplantation in the United States
Deaths as a result of liver failure or HCC) will continue to rise in the next
two decades
Responsible for 85% of cases associated with posttransfusional NANB
hepatitis
Occurs among persons of all ages, highest between 20 to 39 years, with a
male predominance.
Blacks have a substantially higher prevalence of chronic HCV infection than
do whites.
FEB, 17, 2015DR. ARMAAN SINGH 8
9. TRANSMISSION
Mainly blood-borne (transfusion, intravenous drug
abuse)
High risk:Transfusion, intravenous drug abuse
Low risk:
Snorting cocaine or other drugs
Occupational exposure needle stick , health workers
Body piercing and acupuncture with unsterilized needle
Tattooing
From pregnant mother to child
Nonsexual household contacts (rare)
Sharing razors and/or toothbrushes
Sexual transmission
FEB, 17, 2015DR. ARMAAN SINGH 9
11. PATHOGENESIS
Direct cell injury due to viral replication
Genotype 1 is associated with higher viral replication, and infection with the type 1b
genotype is associated with more progressive liver disease
Immune mediated cell injury:
CD8+ and CD4+ lymphocytes in portal, peri-portal, and lobular areas in patients
with HCV infection
FEB, 17, 2015DR. ARMAAN SINGH 11
12. COURSE OF DISEASE
Associated with Acute and Chronic Infections
FEB, 17, 2015DR. ARMAAN SINGH 12
13. COURSE OFTHE DISEASE
Asymptomatic: 30%
Moderate to severe hepatitis in 30% <20 years of age
70-80% develop chronic infection
Presence of viral RNA in serum for 6 months or more
Evidence of viral replication: viral load
10-30% of develop cirrhosis
Factors promoting cirrhosis:
Alcohol use,
Male sex,
Age over 40 years at the time of infection
Co-infection with HIV and/or HBV
The 5-year mortality with compensated cirrhosis 9%,
Decompensated cirrhosis had a 5-year mortality of 50%
FEB, 17, 2015DR. ARMAAN SINGH 13
14. COURSE OFTHE DISEASE,
CONTD; Hepatocellular Carcinoma in HCV infection
1% to 4% of patients per year during the first 5 years
after cirrhosis develop hepatocellular carcinoma
7% after 5 years of cirrhosis
14% at 10 years;
Higher in men
Higher in older patients
FEB, 17, 2015DR. ARMAAN SINGH 14
NIH Consensus Program. National Institutes of Health consensus development conference panel
statement: management of hepatitis C. Hepatology. 1997;26:2S-10S.
16. SPONTANEOUS RESOLUTION
Early studies
15–25% of persons who developed transfusion-associated acute hepatitis C,
14–29% HCV-infected blood donors, persons with ‘community-acquired’ infection, IV drug
abusers and children with leukemia
Later studies:
42 and 45%. among infected children (21, 29), young women (20, 22) and even some
persons with community-acquired hepatitis C
Young age at the time of infection is an important
determinant of the likelihood of spontaneous
recovery.
FEB, 17, 2015DR. ARMAAN SINGH 16
The historyof the‘‘natural history’’of hepatitisC(1968-2009): Liver International 2009; 29(s1): 89–99
17. DIAGNOSIS
Clinical Signs and symptoms: not suggestive, unless thorough history and Labs
Serum anti-HCV antibodies: 99% sensitivity and specificity
Serum HCV RNA: “Viral Load”
Quantitative: used for
Confirmation of Diagnosis
Monitoring response to therapy
Qualitative:
50 IU/ml: 100 copies/mL to confirm diagnosis 98% specificity
AASLD does not recommend qualitative
Liver biopsy: for cirrhosis, prognosis
ALT: Non specific
Genotype: for treatment duration and response
FEB, 17, 2015DR. ARMAAN SINGH 17
18. NOVACCINATION SO FAR
HEPATITIS C PREVENTION
AASLD, (American Association for the Study of Liver Diseases) guidelines-2009
FEB, 17, 2015DR. ARMAAN SINGH 18
19. WHO SHOULD BE SCREENED
Persons who have injected illicit drugs in the recent and remote past
Persons with conditions of a high prevalence of HCV infection including:
With HIV infection
With hemophilia who received clotting factor prior to 1987
Who have ever been on hemodialysis
With unexplained abnormal aminotransferase levels
Immigrants from countries with a high prevalence of HCV infection
Prior recipients of transfusions or organ transplants prior to July 1992:
Persons who were notified that they had received blood from a donor who
later tested positive for HCV infection
Persons who received a transfusion of blood or blood products
Persons who received an organ transplant
Children born to HCV-infected mothers
Health care, emergency medical and public safety workers after a needle stick injury
or mucosal exposure to HCV-positive blood
Current sexual partners of HCV-infected persons
FEB, 17, 2015DR. ARMAAN SINGH 19
20. PREVENTION
NoVaccine is available
Risk factor modification
Intravenous drug abuse: treatment with oral methadone
Sexual contact: appropriate barrier contraception
Avoid blood exposure: Occupational (universal precautions) or other contact
Avoid sharing toothbrushes or razors or receiving a tattoo
HAV and HBV vaccine to prevent further progression of liver disease
FEB, 17, 2015DR. ARMAAN SINGH 20
22. GOALS OF THERAPY
Eradicate HCV infection in acute
Decrease HCV associated morbidity and mortality
Attain SustainedVirologic Response (SVR)
Undetectable HVC RNA, 24 weeks after therapy completion
Normalize biochemical markers
Improve clinical symptoms
Prevent progression to cirrhosis an HCC
Prevent development of end stage liver disease
To prevents the development of chronic HCV infection
FEB, 17, 2015DR. ARMAAN SINGH 22
These goals
are partly achieved by
Pharmacotherapy
23. ACUTE HCV INFECTION
PEG- INF α based therapy for 12-24 weeks
Ribavirin may be added: but no study is available to
favor improve SVR
Treatment can be delayed for 8-12 weeks for to assess
for spontaneous resolution
Meta-analysis of 16 trials resulted in a risk difference of
49% (95% CI 33-65), for developing chronic infection
between treated and untreated patients
FEB, 17, 2015DR. ARMAAN SINGH 23
24. TREATMENT OF CHRONIC HCV
INFECTION Indications of therapy:
Age older than 18 years and positive serum HCV RNA
On biopsy moderate to severe inflammation/necrosis
Compensated liver disease, acceptable hemoglobin (13
g/dL men, 12 g/dL women) and neutrophils (more than
1500/mm3), SCr less than 1.5 mg/dL
Willingness to be treated and be adherent
No contraindications to therapy
FEB, 17, 2015DR. ARMAAN SINGH 24
25. TREATMENT OF CHRONIC HCV
INFECTION Contraindications to treatment
Major uncontrolled depressive disorder
Solid-organ transplantation (renal, heart, lung)
Autoimmune hepatitis or other autoimmune conditions
Untreated thyroid disease
Pregnant or unwilling to adhere to adequate contraception
Severe concurrent medical disease (hypertension, heart failure, coronary heart disease, poorly
controlled diabetes mellitus, chronic obstructive pulmonary disease)
Age younger than 2 years
Hypersensitivity to IFN or ribavirin
FEB, 17, 2015DR. ARMAAN SINGH 25
26. TREATMENT OF CHRONIC HCV
INFECTION Difficult patient population: individualized consideration
Normal ALT (treatment dependent on genotype, degree of fibrosis, symptoms)
Liver biopsy indicating no or mild fibrosis
Advanced liver disease (fibrosis or decompensated cirrhosis)
Recurrence after liver transplantation
Patients younger than 18 years
Co-infection with HIV or HBV
Chronic Kidney Disease
Non responders or relapses
FEB, 17, 2015DR. ARMAAN SINGH 26
27. TREATMENT
First-line treatment for acute HCV includes pegylated interferon plus ribavirin.
once-weekly PEG-IFN and a daily oral dose of ribavirin in two divided doses
FEB, 17, 2015DR. ARMAAN SINGH 27
Genotype Pegylated-IFN
Dose
weight Ribavirin Dose Duration
1 Peginterferon
α2a 180 mcg/wk
Less than 75 Kg 1000 mg 48 weeks
Peginterferon α2b
1.5 mcg/wk
More than 75 kg 1200 mg
2,3 Peginterferon á2a
180 mcg/wk
800 mg 24 weeks
Peginterferon α2b
1.5 mcg/wk
At week 1, 2, 4 and then interval of 4-8 weeks monitor:
•Symptom of Disease
•Side Effects of therapy
•Blood count
•Aminotransferases
28. TREATMENT: GENOTYPE 4
A meta-analysis leads to recommendations for patients with genotype 4:
Combination therapy with Peg IFN plus ribavirin for 48 weeks.
Combination of Peg IFN-α2b plus a fixed dose of ribavirin (10.6mg/kg/day) for 36weeks may
also result in a sufficient EVR.
genotype 6:
with Peg IFN-α plus ribavirin for 48 weeks was more effective than treatment for 24 weeks.
FEB, 17, 2015DR. ARMAAN SINGH 28
30. RIBAVIRIN ADVERSE EFFECT
MONITORING Oral nucleoside analog
Available as 200-mg tablets (Copegus) or capsules (Rebetol)
Adverse Effect
Hemolytic anemia:
Upto 10% of patients (usually within 1–2 weeks of initiating therapy):
decrease dose to 600 mg/day when hemoglobin drops to 10 g/dL or less, and
discontinue when hemoglobin drops to 8.5 g/dL or less
May worsen underlying cardiac disease;
Monitor complete blood cell count (CBC) at baseline, 2 weeks, 4 weeks,
Decrease dose to 600 mg/day if hemoglobin drops more than 2 g/dL in any 4-week
period during treatment.
May use epoetin or darbepoetin to stimulate red blood cell production, improve
anemia
(J Clin Gastroenterol 2005;39:S9-S13),
FEB, 17, 2015DR. ARMAAN SINGH 30
31. RIBAVIRIN ADVERSE EFFECT MONITORING
Teratogenicity: Category X drug;
Requires a negative pregnancy test at baseline and every month up to 6 months after
treatment,
Use of two forms of barrier contraception during treatment and for 6 months after
treatment.
Contraindicated in patients with a creatinine clearance (CrCl) less than 50
mL/minute
pancreatitis, pulmonary dysfunction (dyspnea, pulmonary infiltrate, and
pneumonitis), insomnia, irritability or depression (often referred to as “riba
rage”), and pruritus.
FEB, 17, 2015DR. ARMAAN SINGH 31
32. INTERFERON
FEB, 17, 2015DR. ARMAAN SINGH 32
INF α 2 b:
Used for HBV and HBC infections
Half life : 2-3 hours
Dose: 3 MIU subcutaneous 3 times
/week
Geno-1: 4/48 weeks
Geno2: 3/24 weeks
Peg IFN α2 a: with branched peg
chain
Used for HBV and HVC infections
Half life: 160 hours
Dose: 180 mcg s/c once weekly
Geno-1 4/48
Geno-2 3/24
PegIFN -α2b : linear peg chain
Half life: 40 hours
Dose 1.5 mcg/kg s/c once weekly
IFN alfaxon-1:
Used for HCV treatment
Dose:
naïve: 9 mcg
Non responder: 15 mcg s/c 3 times a
week
Naïve for 24 weeks
INF non responder: 48 weeks
33. INTERFERON:ADVERSE EFFECTS Most Common:
influenza-like symptoms (e.g., fever, headache, myalgia, fatigue),
Hematologic abnormalities: neutropenia, thrombocytopenia,
Neuropsychiatric disorders (e.g., depression 40 % and anxiety),
injection site reactions,
diarrhea, nausea, insomnia, alopecia, pruritis, and anorexia.
Less common but serious adverse
severe psychiatric (i.e., suicidal ideation),
cardiovascular (i.e., myocardial infarction),
Endocrine (e.g., thyroid dysfunction, diabetes mellitus),
immune (e.g., psoriasis, lupus),
pulmonary, and ophthalmologic disorders,
pancreatitis, colitis, and other serious infections.
FEB, 17, 2015DR. ARMAAN SINGH 33
34. MANAGING THE ADVERSE EFFECTS OF
INTERFERON Hematological:
Anemia: common reason for discontinuation and dose reduction (upto 23% of patients)
Tx: Erythropoitic growth factor:
Epoitin Alfa: 40-6000 units weekly
Darbepoitin alfa 3 mcg every 2 weeks
IFN induced neutropenia:
Recombinant granulocyte colony stimulating factor
(filgrastim) is safe and effective
Thrombocytopenia:
Eltrombopag, an orally active thrombopoietin receptor agonist that
received FDA approval for chronic ITP (hepatotoxic)
FEB, 17, 2015DR. ARMAAN SINGH 34
35. MANAGING THE ADVERSE EFFECTS OF
INTERFERON
Neuropsychiatric:
Prompt recognition and early treatment required
Depression: 44% during first 3 months
Tx:
Close monitoring and follow up by a team of health care providers including psychiatrist
Prophylactic anti-depressants are debated
Uncontrolled psychiatric symptoms: contraindication for Tx
FEB, 17, 2015DR. ARMAAN SINGH 35
36. TREATMENT CHALLENGES
High viral load
HCV RNA greater than 800,000 IU/mL
Advanced fibrosis and cirrhosis,
Continued drug and/or alcohol use,
Psychiatric conditions,
Coinfection with HBV or HIV, advanced age,
Immunosuppression (e.g., liver transplantation recipients),
African American race,
Obesity and insulin resistance,
Previous treatment with suboptimal therapy
FEB, 17, 2015DR. ARMAAN SINGH 36
37. AFRICAN AMERICANS: VARIABLE
RESPONSE
Result of 2 prospective , multicenter clinical trials,
In African American patients, SVR occurred in only 19% to 28% of HCV genotype 1
infected African American patients treated with pegIFN and ribavirin therapy, in
contrast to the 40% to 50% seen in other studies
Difference cannot be explained
New strategies: ???
FEB, 17, 2015DR. ARMAAN SINGH 37
38. HIV AND HCV CO-INFECTION
30% HIV patient also have HCV infection
Rapid progression of liver damage
SVR is lower as compared to HVC alone
A threshold CD4 count of at least 350 cells/ L has beenμ
suggested for initiation of antiviral therapy;
Treatment is not recommended if CD4 counts lower than 200
cells/mL.
Adverse effects are more common:
Anemia with Ziduvodine and Ribavirin combination
Mitochondrial toxicity, pancreatitis, liver failure, and death ; more
common with Didanosine and Ribavirin combination
???? Liver transplant
FEB, 17, 2015DR. ARMAAN SINGH 38
39. TREATMENT NONRESPONSIVE OR
RELAPS No specific treatment regimen for chronic HCV infections not responding
to, or relapse after, pegIFN-based therapy.
High-dose IFN alfacon-1 in combination with ribavirin is currently being
evaluated in clinical trials for partial or no response to pegIFN-based
therapy
Extension to 72 weeks: needs evidence
FEB, 17, 2015DR. ARMAAN SINGH 39
40. LIVER TRANSPLANT. IS THIS A
SOLUTION? Most common indication in US:
Hepatitis C virus–related end-stage liver disease
Outcome:
Recurrence is essential outcome
Progression of liver disease is accelerated,Within 5 years after
transplantation, 20% to 40% of liver allografts progress to cirrhosis;
60% to 70% of cirrhotics experience hepatic decompensation within 3
years
Response rates to pegIFN and ribavirin treatment after liver transplant
are lower than for patients in the pretransplant setting,
Drug toxicity remains a limiting factor. 1/3 require discontinuation
FEB, 17, 2015DR. ARMAAN SINGH 40
41. DEALING WITH THE CHALLENGES: NEW
ANTIVIRALS
Direct Acting Antiviral Drugs (DAA)
The NS3 protease inhibitors
Telaprevir and Boceprevir
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011
practiceguideline by the American Association for the Study of Liver Diseases
FEB, 17, 2015DR. ARMAAN SINGH 41
42. TREATMENT UPDATES ADD ON THERAPY FOR
GENOTYPE-1:
Boceprevir: Protease inhibitor : (DAA)
Indicated for:
Adult naïve patients
Who failed previous treatment with Peginferon + ribavirin
SVR rate with triple therapy is 63-66% in comparison to double therapy (50%)
Higher incidence of anemia and neutropenia
Monitor after every 4 weeks
Dose:
800 mg t.i.d. with food (200mg cap available) with double therapy
Added to double therapy at week 5
If RNA viral load is > 100 IU/ml at week 12
Decreased at week 12 but Detectable at week 24
FEB, 17, 2015DR. ARMAAN SINGH 42
Stop
Therapy
43. TREATMENT UPDATES ADD ON THERAPY FOR
GENOTYPE-1
Telaprevir: protease inhibitor
Indicated for:
Adult naïve patients
Who failed previous treatment with Peginferon + ribavirin
SVR rate with triple therapy 72-79% in comparison to double therapy (50%)
Anemia, skin rash, pruritus, nausea, diarrhea, ano-rectal discomfort
Dose:
750 mg t.i.d after 30 minutes of food (with 20 g of fat) for absorption
If Start with double therapy from day 1 continue upto 12 weeks
FEB, 17, 2015DR. ARMAAN SINGH 43
45. OUTCOME EVALUATION PARAMETERS
FEB, 17, 2015DR. ARMAAN SINGH 45
Parameter Definition
Rapid virologic response
(RVR)
Undetectable HCV RNA at week 4 of treatment
Early virologic response (EVR) > 2-log reduction in HCV RNA compared with
baseline or undetectable HCV RNA at 12 weeks
End-of-treatment response
(ETR)
Undetectable HCV RNA at the end of a 24- or 48-
week course depending on genotype
Sustained virologic response
(SVR)
Undetectable HCV RNA 24 weeks after finishing
treatment
Breakthrough Reappearance of HCV RNA while on treatment
Relapse Reappearance of HCV RNA after finishing a course
of treatment
Nonresponder Failure to clear HCV RNA from serum after 24
weeks of therapy
Null responder Failure to decrease HCV RNA by < 2 logs after 24
weeks of therapy
Partial responder Decrease in HCV RNA
46. OUTCOME EVALUATION
Disease:
As discussed above + Check ALT after every 4 weeks
Therapy
Patient on Peginterferone: and Ribavirin or Peginterferone alone:
Check WBC,ANC (absolute neutrophil count ), platelets and Hemoglobin
weekly or biweekly during first month
Monthly after first month
MonitorTSH and fasting lipid panel every 12 weeks
Monitor serum creatinine in patients receiving ribavirin
To avoid ribavirin accumulation in renal insufficiency resulting in Hemolytic
anemia
FEB, 17, 2015DR. ARMAAN SINGH 46
47. PATIENT CARE AND EDUCATION-1
Educate patient for risk factors for acquiring hepatitis
Educate patient about hepatotoxic drugs
Educate regarding vaccination against A & B
Obtain thorough PMH regarding psychiatric, cardiac, endocrine
and renal disorders
Assess fro adverse effects periodically
Encourage for medication compliance to increase SVR
Encourage fluid intake to avoid dehydration
Educate all women of child bearing age, and men who are able
to father a child to use 2 forms of contraception during and 6
months after therapy
FEB, 17, 2015DR. ARMAAN SINGH 47
48. PATIENT CARE AND EDUCATION
CONTD-2
Provide patient education:
How to prevent viral hepatitis
Importance of taking all medication daily at
scheduled time
Adverse effects of medications
How to self administer pegylated interferon
injection correctly
Importance of appropriate disposal of used injection
FEB, 17, 2015DR. ARMAAN SINGH 48
49. REFERENCES
Houghton M Discovery of the hepatitis C virus.Liver Int. 2009
Jan;29 Suppl 1:82-8. doi: 10.1111/j.1478-231.2008.01925.x.
World Health Organization HepatitisC Fact Sheet 2012. http://
www.who.int/ mediacentre/factsheets/ fs164/en/). [Accessed 26 January
2013].
Wise M, Balek S, Fineli L, et al. Changing trends in hepatitis C-related
mortality in the United States, 1995–2004. Hepatology 2008; 47:1128–
1135.
ACCP updates on therapeutics-2011
http://www.annualreviews.org/doi/pdf/10.1146/annurev-pharmtox-
011112-140254
FEB, 17, 2015DR. ARMAAN SINGH 49